ONL Therapeutics Names Industry Veteran as CEO as Company Prepares for First in Human Clinical Trials
June 18, 2019 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., June 18, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving vision in a range of retinal diseases, today...
ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases
May 17, 2017 08:05 ET
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - May 17, 2017) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today...
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
March 28, 2017 08:05 ET
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - Mar 28, 2017) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today...
ONL Therapeutics Receives Nearly $1.0 Million Grant from National Eye Institute for Continued Advancement of ONL1204 Program
March 21, 2017 08:05 ET
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - Mar 21, 2017) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced...
ONL Therapeutics Receives Orphan Drug Designation for ONL1204 for Treatment of Retinal Detachment From FDA
February 11, 2016 08:05 ET
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - Feb 11, 2016) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced...
ONL Therapeutics to Present at the 2015 Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting
October 29, 2015 08:05 ET
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - Oct 29, 2015) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced...
ONL Therapeutics Announces Formation of Scientific Advisory Board
October 14, 2015 08:05 ET
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - Oct 14, 2015) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today...
ONL Therapeutics Provides Update on Novel Photoreceptor Protection Platform for Retinal Diseases
June 15, 2015 08:00 ET
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - Jun 15, 2015) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today provided an...
ONL Therapeutics to Present at Upcoming Investor and Scientific Conferences
March 12, 2015 08:05 ET
|
ONL Therapeutics, Inc.
ANN ARBOR, MI--(Marketwired - Mar 12, 2015) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced...
ONL Therapeutics Announces Management Team Additions
December 03, 2014 08:05 ET
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - Dec 3, 2014) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced...